newsfilter
← Latest News
Business Wire·

Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich's Ataxia

Friedreich's Ataxia is a Rare, Progressive, Life-Shortening, Neuromuscular Disease that Affects Approximately 5,000 Patients in the United States Application Assigned a PDUFA Date of November 30, 2022 If Approved, Omaveloxolone Would Become the Fi